Julie L.C. Kan

1.5k citations

24 papers · 1.0k indexed · h-index 18

Co-authors: Haihong Shen Michael R. Green David Baker Steven S. Smith Bruce E. Kaplan Richard G. Moran James G. Christensen Keith A. Ching
Topics: PI3K/AKT/mTOR signaling in cancer (6 papers)Cancer-related Molecular Pathways (5 papers)RNA and protein synthesis mechanisms (4 papers)
Cited by: Molecular Biology Oncology Cancer Research
Journals: Journal of Biological Chemistry Genes & Development Molecular Cell
Partner nations: United States Taiwan Italy

In The Last Decade

Julie L.C. Kan

24 papers receiving 989 citations

Peers

Countries citing papers authored by Julie L.C. Kan

Since Specialization

Citations

This map shows the geographic impact of Julie L.C. Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie L.C. Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie L.C. Kan more than expected).

Fields of papers citing papers by Julie L.C. Kan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie L.C. Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie L.C. Kan. The network helps show where Julie L.C. Kan may publish in the future.

Co-authorship network of co-authors of Julie L.C. Kan

This figure shows the co-authorship network connecting the top 25 collaborators of Julie L.C. Kan. A scholar is included among the top collaborators of Julie L.C. Kan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie L.C. Kan. Julie L.C. Kan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models 2019 ·Scientific Reports ·Simon P. Langdon,Charlene Kay,In Hwa Um,Michael Dodds,Morwenna Muir,Grant C. Sellar,Julie L.C. Kan,Charlie Gourley,David J. Harrison	22
2	Abstract LB-136: Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer 2014 ·Cancer Research ·Nathan V. Lee,Jing Yuan,(unknown),Joan Cao,Cory L. Painter,John Chionis,Chaoting Liu,David J. Shields,Julie L.C. Kan,Kim Arndt,Todd VanArsdale	3
3	Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871) 2013 ·Molecular Cancer Therapeutics ·Adam Pavlı́c̀ek,Maruja E. Lira,Nathan V. Lee,Keith A. Ching,Jingjing Ye,Joan Cao,(unknown),Kenneth E. Hook,Mark Ozeck,Stephanie T. Shi,Jing Yuan,Xianxian Zheng,Paul A. Rejto,Julie L.C. Kan,James G. Christensen	31
4	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer 2013 ·Frontiers in Pharmacology ·Erica L. Bradshaw‐Pierce,Todd M. Pitts,Aik Choon Tan,(unknown),Mark A. West,Daniel L. Gustafson,Charles Halsey,Leslie Nguyen,Nathan V. Lee,Julie L.C. Kan,Brion W. Murray,Sabine Eckhardt	29
5	An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 2012 ·Molecular Cancer Therapeutics ·Kenneth E. Hook,(unknown),Maruja E. Lira,Keith A. Ching,Nathan V. Lee,Joan Cao,Jing Yuan,Jingjing Ye,Mark Ozeck,Stephanie T. Shi,Xianxian Zheng,Paul A. Rejto,Julie L.C. Kan,James G. Christensen,Adam Pavlı́c̀ek	77
6	Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice 2012 ·Cancer Chemotherapy and Pharmacology ·Brett H. Simmons,Joseph H. Lee,(unknown),Anand Giddabasappa,(unknown),Anthony Wong,Patrick B. Lappin,Jeetendra Eswaraka,Julie L.C. Kan,James G. Christensen,Farbod Shojaei	19
7	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer 2011 ·Molecular Cancer Therapeutics ·(unknown),Keith A. Ching,Julie L.C. Kan,Hwang-Phill Kim,Sae‐Won Han,Seock‐Ah Im,Tae‐You Kim,James G. Christensen,Do‐Youn Oh,Yung‐Jue Bang	58
8	Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model 2011 ·Clinical & Experimental Metastasis ·Gretchen Argast,Joseph S. Krueger,Stuart Thomson,(unknown),(unknown),(unknown),Matthew O’Connor,Peter Mercado,Iain J. Mulford,(unknown),(unknown),Robert A. Wild,Jonathan A. Pachter,Julie L.C. Kan,John D. Haley,Maryland Rosenfeld-Franklin,David Epstein	52
9	Cooperative Signaling between Oncostatin M, Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models 2010 ·Cells Tissues Organs ·Gretchen Argast,Peter Mercado,Iain J. Mulford,Matthew O’Connor,(unknown),Salam Shaaban,David Epstein,Jonathan A. Pachter,Julie L.C. Kan	24
10	Abstract 2615: Amplification and/or high expression of Myc family genes sensitizes tumor cells to aurora kinase inhibitors 2010 ·Cancer Research ·Kenneth E. Hook,Adam Pavlı́c̀ek,(unknown),Maruja E. Lira,(unknown),Julie L.C. Kan,Sreesha P. Srinivasa,James G. Christensen	1
11	Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma 2009 ·Journal of Biological Chemistry ·Jing Wang,Ashwani Rajput,Julie L.C. Kan,Rebecca Rose,Xiaoqiong Liu,Karen K. Kuropatwinski,Jennie Hauser,(unknown),(unknown),(unknown),(unknown),Charles LeVea,(unknown),(unknown),Neil W. Gibson,Michael G. Brattain	65
12	Activation of ERK mitogen-activated protein kinase in human cells by the mycotoxin patulin 2005 ·Toxicology and Applied Pharmacology ·Tsu‐Yang Wu,Feng‐Yih Yu,Chuan Su,Julie L.C. Kan,(unknown),Biing-Hui Liu	29
13	Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs) 2005 ·Bioorganic & Medicinal Chemistry Letters ·Mark J. Mulvihill,Julie L.C. Kan,Patricia Beck,Mark Bittner,(unknown),Andrew Cooke,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Shannon L. Winski,Arlindo L. Castelhano,David Emerson,Neil W. Gibson	14
14	Arginine-Serine-Rich Domains Bound at Splicing Enhancers Contact the Branchpoint to Promote Prespliceosome Assembly 2004 ·Molecular Cell ·Haihong Shen,Julie L.C. Kan,Michael R. Green	201
15	A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2 2004 ·RNA ·Haihong Shen,Julie L.C. Kan,Claudia Ghigna,Giuseppe Biamonti,Michael R. Green	49
16	Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor 1999 ·Genes & Development ·Julie L.C. Kan,(unknown)	128
17	Analysis of a Mouse Gene Encoding Three Steps of Purine Synthesis Reveals Use of an Intronic Polyadenylation Signal without Alternative Exon Usage 1995 ·Journal of Biological Chemistry ·Julie L.C. Kan,Richard G. Moran	20
18	Mouse cDNAs encoding a trifunctional protein of de novo purine synthesis and a related single-domain glycinamide ribonucleotide synthetase 1993 ·Gene ·Julie L.C. Kan,Mehrdad Jannatipour,Shirley M. Taylor,Richard G. Moran	24
19	Recognition of unusual DNA structures by human DNA(cytosine-5)methyltransferase 1991 ·Journal of Molecular Biology ·Steven S. Smith,Julie L.C. Kan,David Baker,Bruce E. Kaplan,(unknown)	93
20	Recognition of structural perturbations in DNA by human DNA(cytosine-5)methyltransferase 1988 ·Gene ·David Baker,Julie L.C. Kan,Steven S. Smith	23

About Julie L.C. Kan

Julie L.C. Kan is a scholar working on Oncology, Molecular Biology and Hepatology, having authored 24 papers that have together received 1.0k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer-related Molecular Pathways (5 papers) and RNA and protein synthesis mechanisms (4 papers). The work is most often cited by research in Molecular Biology (778 citations), Oncology (227 citations) and Cancer Research (118 citations). Julie L.C. Kan has collaborated with scholars based in United States, Taiwan and Italy. Frequent co-authors include Haihong Shen, Michael R. Green, David Baker, Steven S. Smith, Bruce E. Kaplan, Richard G. Moran, James G. Christensen, Keith A. Ching, Claudia Ghigna and Giuseppe Biamonti. Their work appears in journals such as Journal of Biological Chemistry, Genes & Development and Molecular Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact